News

Novartis could overtake Pfizer as No. 1, while Merck's Januvia/Janumet franchise will approach $10 billion in annual sales

Attempts were made to relabel stolen product with counterfeit labels, says NJ Star-Ledger

Combination will create the world's largest single buyer of pharmaceuticals

FDA Safety and Innovation Act is ready for final passage

FedEx takes precautionary steps to manage CO2 outgassing in their newest B-777 aircraft

Meanwhile, all eyes were on the Supreme Court’s expected ruling on Obamacare

Systech builds on its packaging execution/serialization capabilities with an acquisition

Private-equity firm builds a competitor in pharma sales analytics

Private-equity firm builds a competitor in pharma sales analytics

Monoclonal antibodies (MAbs) for oncology will be initial target

The leading chain pharmacy steps up its role as healthcare provider and partner to pharma

Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension

Compiling and maintaining lists of healthcare provider contacts is a bigger and more important task than ever

House bill mostly parallels Senate’s S.3187; but lacks federal pedigree rules

Biopharma remains a bright spot in US and international economic activity, even while the overall outlook remains cloudy

Latest annual Progressions report highlights the shift to healthy behaviors

Tomorrow's healthcare market, driven by consumer choice and outcomes-driven economics, will create new supply chain models

Merger is not expected to affect specialty-distribution agreements negatively

Ten-year BLS projection sees a healthy industry ahead

Patient office visits, prescription usage continued to decline

Pharma industry serves best as underwriter of healthcare providers' efforts

Covis Pharmaceuticals' business model is to acquire distribution rights to low-volume drugs

Applying a consistent framework to choose locations can help optimize R&D and drive cost reduction for pharmaceutical companies of all sizes

US patients believe they are healthier than they actually are, and at the same time have a greater willingness to try new therapies

US patients believe they are healthier than they actually are, and at the same time have a greater willingness to try new therapies

Despite the lack of headlines today as compared to late last year, the drug-shortage situation has not improved. FDA, congressional and industry actions are beginning the change the dynamic

Sampling and doctors’ meetings compete for the largest secondary promotional spending component, behind detailing, in the BRIC countries

Biggest impact is expansion of user fees paid to FDA by generic and medical device manufacturers; drug approvals could be accelerated by changed review process; federal drug pedigree rules are 'on life support' but could still pass